[
  {
    "ts": null,
    "headline": "Final Trade: DAL, AXP, PFE, HMY",
    "summary": "The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.",
    "url": "https://finnhub.io/api/news?id=542bcf1d55209380e30db0abfb233ff3b780a8e5360d5dec3ecab646c4bb34d5",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764180433,
      "headline": "Final Trade: DAL, AXP, PFE, HMY",
      "id": 137622269,
      "image": "https://image.cnbcfm.com/api/v1/image/108232833-17641983011764198299-42711762845-1080pnbcnews.jpg?v=1764198300&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.",
      "url": "https://finnhub.io/api/news?id=542bcf1d55209380e30db0abfb233ff3b780a8e5360d5dec3ecab646c4bb34d5"
    }
  },
  {
    "ts": null,
    "headline": "CMS Slashes Prices Of 15 Major Drugs - Here's Why Pharma Valuations Won't Suffer",
    "summary": "Discover how new U.S. Medicare drug price cuts impact major pharma stocks like Novo Nordisk and why sector resilience supports a strong outlook. Click for more.",
    "url": "https://finnhub.io/api/news?id=1f6a4babd9bee8ff46ea9bfd57aa2d2c9e4fb232cd4ea10363ae33b37483d4b4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764176336,
      "headline": "CMS Slashes Prices Of 15 Major Drugs - Here's Why Pharma Valuations Won't Suffer",
      "id": 137615519,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1407294139/image_1407294139.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover how new U.S. Medicare drug price cuts impact major pharma stocks like Novo Nordisk and why sector resilience supports a strong outlook. Click for more.",
      "url": "https://finnhub.io/api/news?id=1f6a4babd9bee8ff46ea9bfd57aa2d2c9e4fb232cd4ea10363ae33b37483d4b4"
    }
  },
  {
    "ts": null,
    "headline": "NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes",
    "summary": "Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.",
    "url": "https://finnhub.io/api/news?id=7422f7ebf24e12958fe290a02a04ecd3ed66d23588ed2de2710b3c019b0abfac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764171900,
      "headline": "NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes",
      "id": 137614447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.",
      "url": "https://finnhub.io/api/news?id=7422f7ebf24e12958fe290a02a04ecd3ed66d23588ed2de2710b3c019b0abfac"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights",
    "summary": "ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.",
    "url": "https://finnhub.io/api/news?id=6ac81ded30baa5da034478881631ffce1a918e07dea7f3e46eead3cfc0a99ab1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764171720,
      "headline": "AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights",
      "id": 137614448,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.",
      "url": "https://finnhub.io/api/news?id=6ac81ded30baa5da034478881631ffce1a918e07dea7f3e46eead3cfc0a99ab1"
    }
  },
  {
    "ts": null,
    "headline": "Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies",
    "summary": "Pharma companies are facing pricing pressure from several directions, including from the U.S. Medicare negotiations",
    "url": "https://finnhub.io/api/news?id=88b71e4c01ec422b59073a29aa50ec62b533a6d7d826368bff9384a4b21a2226",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764159509,
      "headline": "Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies",
      "id": 137613711,
      "image": "https://image.cnbcfm.com/api/v1/image/108226743-1763385742494-gettyimages-2212016375-NOVO_WEGOVY.jpeg?v=1763385821&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "Pharma companies are facing pricing pressure from several directions, including from the U.S. Medicare negotiations",
      "url": "https://finnhub.io/api/news?id=88b71e4c01ec422b59073a29aa50ec62b533a6d7d826368bff9384a4b21a2226"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Wednesday: Dell, HP, Workday, Deere",
    "summary": "↗️ Dell (DELL): The computer and software maker raised full-year guidance and forecast AI server shipments would more than double. Shares rose nearly 5% premarket. ↘️ HP (HPQ): The computer and printer maker plans to cut up to 10% of its workforce as it invests further in artificial intelligence.",
    "url": "https://finnhub.io/api/news?id=f1b3822132d791fb62e8d5987e3d7c60a60d09065a21d7b5949be7f2cc86c81b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764157395,
      "headline": "Stocks to Watch Wednesday: Dell, HP, Workday, Deere",
      "id": 137611346,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "↗️ Dell (DELL): The computer and software maker raised full-year guidance and forecast AI server shipments would more than double. Shares rose nearly 5% premarket. ↘️ HP (HPQ): The computer and printer maker plans to cut up to 10% of its workforce as it invests further in artificial intelligence.",
      "url": "https://finnhub.io/api/news?id=f1b3822132d791fb62e8d5987e3d7c60a60d09065a21d7b5949be7f2cc86c81b"
    }
  },
  {
    "ts": null,
    "headline": "Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study",
    "summary": "Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in the trial.",
    "url": "https://finnhub.io/api/news?id=854244fc9c852bfdf15884fab8b35a907316d075bbcd4195f9c17ffedf58ae5c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764157020,
      "headline": "Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study",
      "id": 137611445,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in the trial.",
      "url": "https://finnhub.io/api/news?id=854244fc9c852bfdf15884fab8b35a907316d075bbcd4195f9c17ffedf58ae5c"
    }
  },
  {
    "ts": null,
    "headline": "Centers for Medicare & Medicaid Services Unveils $12 Billion Net Savings From Reduction in Drug Prices",
    "summary": "The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,",
    "url": "https://finnhub.io/api/news?id=ed453e3d99118aaec5caa763ba61f4f17ea380d03972a2844140b4163ff336ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764151222,
      "headline": "Centers for Medicare & Medicaid Services Unveils $12 Billion Net Savings From Reduction in Drug Prices",
      "id": 137611270,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,",
      "url": "https://finnhub.io/api/news?id=ed453e3d99118aaec5caa763ba61f4f17ea380d03972a2844140b4163ff336ee"
    }
  },
  {
    "ts": null,
    "headline": "Did Pfizer Just Say \"Checkmate\" to Novo Nordisk?",
    "summary": "The weight loss drug market may approach almost $100 billion by the end of the decade.",
    "url": "https://finnhub.io/api/news?id=b30b4cd1f3a84357ae367cd118fe2c01deb185a5b1a837a9949b5ef9aa751525",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764148500,
      "headline": "Did Pfizer Just Say \"Checkmate\" to Novo Nordisk?",
      "id": 137611230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The weight loss drug market may approach almost $100 billion by the end of the decade.",
      "url": "https://finnhub.io/api/news?id=b30b4cd1f3a84357ae367cd118fe2c01deb185a5b1a837a9949b5ef9aa751525"
    }
  },
  {
    "ts": null,
    "headline": "Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate",
    "summary": "Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo safety concerns observed in any age group by an independent Data Monitoring Committee (DMC)Results confirm benefits of a yearly vaccination prior to each Lyme season Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease va",
    "url": "https://finnhub.io/api/news?id=d305bc3e830524d4b0ff85eb37496975db0915648c01efd1a63f9fa3e3aeb2f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764136800,
      "headline": "Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate",
      "id": 137611448,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo safety concerns observed in any age group by an independent Data Monitoring Committee (DMC)Results confirm benefits of a yearly vaccination prior to each Lyme season Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease va",
      "url": "https://finnhub.io/api/news?id=d305bc3e830524d4b0ff85eb37496975db0915648c01efd1a63f9fa3e3aeb2f9"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Negotiates Lower Prices for Ozempic and 14 Other Drugs",
    "summary": "The U.S. government negotiated lower prices in the federal Medicare program for 15 high-selling medicines including Ozempic, widening an effort to rein in drug costs.  The new prices, which will take effect in 2027, shave 38% to 85% off the list prices for drugs for diseases including asthma, cancer and diabetes.  The reductions are estimated to save Medicare, the health-insurance program for the elderly, $12 billion.",
    "url": "https://finnhub.io/api/news?id=1c30417e270008628fa06e7b14fa125df9b5828a9df713babb9b2f8a3c4b1378",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764116520,
      "headline": "U.S. Negotiates Lower Prices for Ozempic and 14 Other Drugs",
      "id": 137611352,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The U.S. government negotiated lower prices in the federal Medicare program for 15 high-selling medicines including Ozempic, widening an effort to rein in drug costs.  The new prices, which will take effect in 2027, shave 38% to 85% off the list prices for drugs for diseases including asthma, cancer and diabetes.  The reductions are estimated to save Medicare, the health-insurance program for the elderly, $12 billion.",
      "url": "https://finnhub.io/api/news?id=1c30417e270008628fa06e7b14fa125df9b5828a9df713babb9b2f8a3c4b1378"
    }
  }
]